New hope for patients stricken by Immunotherapy's dangerous blood side effects
NCT ID NCT07303881
Summary
This study is testing an experimental drug called golidocitinib for patients with advanced lung cancer. These patients are experiencing severe, hard-to-treat blood-related side effects (like very low blood cell counts) caused by their immunotherapy. The main goal is to see if golidocitinib is safe and can help bring these dangerous blood counts back to normal levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Guangzhou Medical College
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.